Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials

A. Poli, A. Corsini

Research output: Contribution to journalArticlepeer-review

Abstract

A number of clinical trials have confirmed that statin treatment and, more generally, LDL-lowering treatment, are able to reduce CHD and CVD events in a wide range of clinical conditions associated with increased cardiovascular risk. However, the most recent trials have also identified patient groups in which lipid-lowering treatment shows a more limited preventive potential due to the "non-reversibility" of part of the cardiovascular risk, which dilutes the observed treatment effect by events that are not directly a consequence of atherosclerosis. The use of lipid-lowering therapy in these patients should be driven not only by their absolute risk, as suggested by the most recent American and European guidelines, but also by their overall clinical setting and by the evidence of benefit obtained in controlled trials in comparable populations.

Original languageEnglish
Pages (from-to)372-373
Number of pages2
JournalEuropean Journal of Internal Medicine
Volume21
Issue number5
DOIs
Publication statusPublished - Oct 2010

Keywords

  • Atherosclerosis
  • Ezetimibe
  • Lipid-lowering drugs
  • Statins

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials'. Together they form a unique fingerprint.

Cite this